MIRM - Mirum Pharmaceuticals Inc logo

Mirum Pharmaceuticals Inc

MIRM
Revenue grew 100% of years5Y
Compare MIRM Hold

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its products include LIVMARLI for Alagille syndrome, Cholbam for bile acid synthesis disorders, and Chenodal for radiolucent gallbladder stones, among others.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$5,948today

Score Overview

1 Year
Score
Net Growth-36x
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth28.67%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.4
Net Growth-8x
Net Trend40%
Net Income Consistencyโ€”
Rev Growth35x
Rev TrendEvery year
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-15x
Net Trend43%
Net Income Consistency
Rev Growthโ€”
Rev TrendEvery year
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Mirum Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. MIRM does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 91.95โ€”
1 Year2025-11-17
$ 72.2127.34%
5 Years2021-11-17
$ 15.46494.76%
All Time2019-07-18
$ 13.216x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 670M-$ 903M$ 373M
2025$ 521M-$ 23M$ 383M
2024$ 336M-$ 87M$ 280M
2023$ 186M-$ 163M$ 286M
2022$ 77M-$ 135M$ 151M
2021$ 19M-$ 83M$ 156M
2020$ 11M-$ 103M$ 231M
IPO2019$ 0.00-$ 52M$ 116M
MIRM - Mirum Pharmaceuticals Inc logo

Mirum Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 11M to $ 521M and net income went from -$ 103M to -$ 23M. Revenue increased in every one of those 5 years; net income in 2.

Mirum Pharmaceuticals Inc currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.

Membership

Explore MIRM with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies